A PHASE 1/2 DOSE ESCALATION AND DOSE
EXPANSION STUDY OF BA3021 IN PATIENTS WITH
ADVANCED SOLID TUMORS
The purpose of this research study is to test the safety of different doses of the study drug, BA3021, and to find out what good and bad effects it may have in men and women with locally advanced or metastatic solid tumor.
Advanced solid tumor that have failed available standard of care therapy and express the ROR2 protein.
1. Men and women 18 years or older
2. Locally advanced or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
The study is planned to last for about 2 ½ years. You will receive the study drug for as long as you and the investigator feel that you are tolerating the study drug and the investigator feels it is in your best interest to continue receiving study drug; you follow directions of the investigator; or if you are female and able to become pregnant, you do not become pregnant. After you finish treatment, you will have safety follow-up visits to see how you are feeling 3 months from your last dose of study drug. Thereafter, your
investigator will continue to watch you for side effects and follow your condition every 3 months by telephone.
Knight Clinical Trials Information Line